Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

Peter Martin, Nancy L. Bartlett, Julio C. Chavez, John L. Reagan, Sonali M. Smith, Ann S. LaCasce, Jeffrey Jones, James Drew, Chengqing Wu, Erin Mulvey, Maria V. Revuelta, Leandro Cerchietti, John P. Leonard

Blood (2022) 139 (8): 1147–1159.

https://doi.org/10.1182/blood.2021011679

Published: 2022

Includes: Supplemental data

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Marek Trněný, MD, John P. Leonard, MD, Huilai Zhang, MD, Grzegorz Nowakowski, MD, Koji Izutsu, MD PhD, Nathan H. Fowler, MD, Catherine Thieblemont, MD PhD, Pier Luigi Zinzani, MD PhD, Stacey Kalambakas, MD, Myron Czuczman, Pierre Fustier, PhD, Chengqing Wu, PhD, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 347.

https://doi.org/10.1182/blood-2019-122461

Published: 2019

Journal Articles

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 445.

https://doi.org/10.1182/blood-2018-99-110861

Published: 2018

Journal Articles

Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Peter Martin, FRCPC, MD MS, Nancy L. Bartlett, MD, Julio C. Chavez, MD, John L. Reagan, MD, Sonali M. Smith, MD, Ann S. LaCasce, MD MSc, Jeffrey A. Jones, MD MPH, James Drew, MA, Chengqing Wu, PhD, Leandro Cerchietti, MD, John P. Leonard, MD

Blood (2018) 132 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2018-99-114438

Published: 2018

Journal Articles

A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma

Peter Martin, MD, Nancy L. Bartlett, MD, Ildefonso Ismael Rodriguez Rivera, MD, Maria Revuelta, PhD, Julio C. Chavez, MD, John L. Reagan, MD, Sonali M. Smith, MD, Ann S. LaCasce, MD, Lei Zhang, MD, Merry Zhai, BS, Chengqing Wu, PhD, John P. Leonard, MD, Leandro Cerchietti, MD

Blood (2017) 130 (Supplement 1): 192.

https://doi.org/10.1182/blood.V130.Suppl_1.192.192

Published: 2017

Journal Articles

Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs)

Valeria Santini, MD, Pierre Fenaux, MD PhD, Aristoteles Giagounidis, Uwe Platzbecker, MD, Alan F List, MD, Jianhua Zhong, PhD, Chengqing Wu, PhD, Konstantinos Mavrommatis, C.L. Beach, PharmD, Albert Hoenekopp, MD, Kyle J. MacBeth, PhD

Blood (2016) 128 (22): 225.

https://doi.org/10.1182/blood.V128.22.225.225

Published: 2016

Journal Articles

Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies

Aristoteles Giagounidis, MD PhD, Alan F. List, MD, Eva Hellström-Lindberg, MD PhD, Ghulam J. Mufti, MD PhD, Brigitte Schlegelberger, MD PhD, John Morrill, Chengqing Wu, PhD, Barry S. Skikne, MD, Pierre Fenaux, MD PhD, Gudrun Göhring, MD

Blood (2015) 126 (23): 1680.

https://doi.org/10.1182/blood.V126.23.1680.1680

Published: 2015

Journal Articles

Prevalence and Clinical Impact of Additional Cytogenetic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Deletion 5q from the MDS-003 and MDS-004 Studies

Aristoteles Giagounidis, MD PhD, Alan F. List, MD, Eva Hellstrom-Lindberg, MD PhD, Ghulam J. Mufti, MD PhD, Brigitte Schlegelberger, MD PhD, John Morrill, Chengqing Wu, PhD, Barry Skikne, MD, Pierre Fenaux, MD PhD, Gudrun Göhring, MD

Blood (2014) 124 (21): 3270.

https://doi.org/10.1182/blood.V124.21.3270.3270

Published: 2014

Journal Articles

Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004

Aristoteles Giagounidis, MD, PhD, Alan List, MD, Eva Hellström-Lindberg, MD, PhD, Mikkael A. Sekeres, MD, MS, Ghulam J. Mufti, MD, PhD, Brigitte Schlegelberger, MD, PhD, John Morrill, Chengqing Wu, Barry S. Skikne, MD, Pierre Fenaux, MD, PhD, Gudrun Göhring, MD

Blood (2013) 122 (21): 1538.

https://doi.org/10.1182/blood.V122.21.1538.1538

Published: 2013

NARROW

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma

Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs)

Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies

Prevalence and Clinical Impact of Additional Cytogenetic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Deletion 5q from the MDS-003 and MDS-004 Studies

Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only